Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Large cell neuroendocrine carcinoma of the lung with cancer-associated retinopathy.
Nakamura T, Fujisaka Y, Tamura Y, Tsuji H, Matsunaga N, Yoshida S, Imanishi M, Fujita K, Ikeda S, Oku H, Goto I, Ikeda T, Hanafusa T. Nakamura T, et al. Among authors: fujisaka y. Case Rep Oncol. 2015 Mar 7;8(1):153-8. doi: 10.1159/000380943. eCollection 2015 Jan-Apr. Case Rep Oncol. 2015. PMID: 25873883 Free PMC article.
Phase I/II Study of Cisplatin plus Nab-Paclitaxel with Concurrent Thoracic Radiotherapy for Patients with Locally Advanced Non-Small Cell Lung Cancer.
Hayashi H, Ogura M, Niwa T, Yokoyama T, Tanizaki J, Ozaki T, Yoshioka H, Kurata T, Tamura Y, Fujisaka Y, Tanaka K, Hasegawa Y, Kudo K, Chiba Y, Nakagawa K. Hayashi H, et al. Among authors: fujisaka y. Oncologist. 2021 Jan;26(1):19-e52. doi: 10.1002/ONCO.13524. Epub 2020 Sep 28. Oncologist. 2021. PMID: 32918791 Free PMC article. Clinical Trial.
Comparison Between Second- and Third-generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors as First-line Treatment in Patients With Non-small-cell Lung Cancer: A Retrospective Analysis.
Mitsuya S, Tsuruoka K, Kanaoka K, Funamoto T, Tsuji H, Matsunaga N, Nakamura T, Tamura Y, Imanishi M, Ikeda S, Fujisaka Y, Goto I, Imagawa A. Mitsuya S, et al. Among authors: fujisaka y. Anticancer Res. 2021 Oct;41(10):5137-5145. doi: 10.21873/anticanres.15331. Anticancer Res. 2021. PMID: 34593465
Severe Drug-Induced Interstitial Lung Disease After Administration of Osimertinib as Adjuvant Treatment for Resected EGFR-Mutated NSCLC: A Case Report.
Mitsuya S, Arai M, Kanaoka K, Funamoto T, Tsuji H, Tsuruoka K, Matsunaga N, Nakamura T, Tamura Y, Imanishi M, Ikeda S, Imagawa A, Fujisaka Y. Mitsuya S, et al. Among authors: fujisaka y. JTO Clin Res Rep. 2024 Jan 5;5(2):100631. doi: 10.1016/j.jtocrr.2024.100631. eCollection 2024 Feb. JTO Clin Res Rep. 2024. PMID: 38322711 Free PMC article.
Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS).
Katakami N, Yokoyama T, Morita S, Okamoto T, Urata Y, Hattori Y, Iwamoto Y, Sato Y, Ikeda N, Takahashi T, Daga H, Oguri T, Fujisaka Y, Nishino K, Sugawara S, Kozuki T, Oki M, Yamamoto N, Nakagawa K. Katakami N, et al. Among authors: fujisaka y. Int J Clin Oncol. 2023 Jan;28(1):79-88. doi: 10.1007/s10147-022-02266-x. Epub 2022 Nov 21. Int J Clin Oncol. 2023. PMID: 36414827 Clinical Trial.
60 results